Back to search results

Study of IMP1734 for Advanced Solid Tumors

This study is testing a new drug called IMP1734, which is a PARP1 selective inhibitor (a type of drug that targets a specific protein in cancer cells). It's for people aged 18 to 89 with advanced solid tumors, including certain types of breast cancer, ovarian cancer, or prostate cancer, who have already received some prior treatments. The main goals are to see how safe IMP1734 is, what side effects it might cause, and to find the highest dose that can be given safely. The study also looks at how the body handles the drug and if it shows any early signs of working. This study is currently recruiting about 156 participants.

Study design
This is an interventional study with an unspecified phase, meaning participants will receive the study drug IMP1734. It will involve about 156 participants and has two parts: a dose escalation phase and a dose optimization phase.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Safety will be monitored from consent until 30 days (plus 7 days) after your last dose of IMP1734.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06253130

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Recruiting
PHASE1Ages 18–89InterventionalTreatment
Eikon Therapeutics
~156 participants
Updated 2026-06-15 on ClinicalTrials.gov
What's tested:IMP1734

At a glance

Recruiting sites
46 of 57 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of subjects with adverse events, treatment emergent adverse events or serious adverse events
Measured over Consent to 30 + 7 days post last dose of IMP1734
+1 more outcome measured

Conditions

Advanced Solid Tumor

Explore related trials

Breast CarcinomaFallopian Tube CarcinomaMalignant Ovarian NeoplasmPrimary Peritoneal CancerProstate CarcinomaSolid NeoplasmAHRR Gene

Where it's being run

57 sites across 36 states
Spain7
California4
Queensland4
China4
Michigan3
Florida2
Tennessee2
Ontario2

Study leadership

  • Viola Chen, MD · STUDY_DIRECTOR · Eikon Therapeutics

Who to contact

Nicola Lynch
[email protected]
212-540-4923 · ext. 104923
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Breast cancer; must have received at least one prior chemotherapy in neoadjuvant/adjuvant/metastatic setting, must have received hormonal therapy if HR+,
HGSOC or high grade endometrioid EOC, fallopian tube or primary peritoneal cancer; must have received at least one prior platinum-based chemotherapy for advanced disease
mCRPC with ongoing ADT, must have received NHA and up to 1 prior line of taxane chemotherapy
Age ≥ 18 years at the time of informed consent
Eastern Cooperative Oncology Group (ECOG) performance status ≤1
Adequate organ function
Life expectancy ≥ 12 weeks
Should have evaluable disease as defined by RECIST1.1 and/or CA125 or PSA
Female subjects of childbearing potential and male subjects must agree to use an effective method of contraception from study entry up to 6 months after the last dose of IMP1734
deleterious or suspected deleterious germline or somatic mutations of select HRR genes
up to 1 prior line of PARP inhibitor containing treatment

Exclusion

Any investigational or approved anti-cancer therapies administered within 28 days/ before the first dose of IMP1734
Have received prior PARP1 selective inhibitors
Mean resting QTcF \> 470 ms or QTcF \< 340 ms
Active or untreated central nervous system (CNS) metastases and/or carcinomatous meningitis.
Infections
Any known predisposition to bleeding
Unable to swallow oral medications OR have malabsorption syndrome or any other uncontrolled gastrointestinal condition that might impair the bioavailability

What this trial measures

  • Number of subjects with adverse events, treatment emergent adverse events or serious adverse eventsConsent to 30 + 7 days post last dose of IMP1734

    Number of subjects reporting adverse events or serious adverse events which include any abnormal clinical events, laboratory assessments outside of normal clinical range, abnormal vital signs observed, and any abnormal ECG parameters

  • Maxim Tolerated Dose or Recommended Dose for ExpansionDLT period is from the first dose of the study drug until the last day of the first cycle

    Number of patients that experience a DLT or any toxicity which occurs from the time of the first dose of study drug until the end of cycle 1, which is deemed unrelated to the disease.